Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM's medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch in the U.S. The Exceed system from MT.DERM is the world's only dual-indicated, FDA-cleared medical microneedling device. It is clinically proven to dramatically reduce the appearance of facial wrinkles and facial acne scars. Candela manufactures and distributes the Profound system, the only real-time, temperature-controlled, long pulse radiofrequency (RF) microneedling device. "We are delighted to enter into a partnership with MT.DERM, based on its superior engineering and deep understanding of needling technology," said Geoffrey Crouse, CEO of Candela. "Microneedling is an essential component of any medical aesthetics practice. The addition of the Exceed medical microneedling system strengthens Candela's product portfolio, which continues to provide customers the most comprehensive offering of best-in-class medical aesthetic technologies."